Projecting the Long‐Term Cost‐Effectiveness of Once‐Weekly Insulin Icodec Versus Once‐Daily Basal Insulin Analogs in Italy Using the Prime T2D Model
Authors' conclusion
Icodec was projected to be cost-effective versus once-daily insulins for insulin-naïve people with T2D in Italy.
Study context
- Population
- Modelled insulin-naïve adults with T2D in Italy; baseline characteristics and treatment effects from ONWARDS 1, 3 and 5
- Comparison
- Once-weekly insulin icodec vs once-daily basal insulins
- Outcome
- Quality-adjusted life expectancy and ICER
- Follow-up
- Patient lifetimes
Methodological detailsmodelling study, PRIME T2D Model, lifetime horizon (up to 60 years), discounted annually at 3.0%, Italian National Health Service perspective, Basal insulins for 4 years, then intensification with bolus insulin; first-year treatment effects and once-weekly utility benefit maintained until intensification
- Modelling study
- PRIME T2D Model
- Lifetime horizon (up to 60 years)
- Discounted annually at 3.0%
- Italian National Health Service perspective
- Basal insulins for 4 years, then intensification with bolus insulin; first-year treatment effects and once-weekly utility benefit maintained until intensification
Main finding
As reported in the abstract
patient lifetimes
- Icodec vs Glargine U100
- incremental quality-adjusted life years (QALYs) 0.16 QALYs
- Icodec vs Degludec
- incremental QALYs 0.16 QALYs
- Icodec vs Once-daily insulin mix
- incremental QALYs 0.26 QALYs
- Icodec vs Glargine U100
- ICER 25 623 euros (EUR) per QALY gained
- Icodec vs Degludec
- ICER 5438 EUR per QALY gained
- Icodec vs Once-daily insulin mix
- ICER 3940 EUR per QALY gained
Original publication
Projecting the Long‐Term Cost‐Effectiveness of Once‐Weekly Insulin Icodec Versus Once‐Daily Basal Insulin Analogs in Italy Using the Prime T2D Model. Diabetes Obes Metab. Published 31 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →